Lessons From Ximelagatran: Issues for Future Studies Evaluating New Oral Direct Thrombin Inhibitors for Venous Thromboembolism Prophylaxis in Orthopedic Surgery

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 3, 2009, Pages 316-326

  Lazo Langner, Alejandro ^a   Rodger, Marc A ^b   Wells, Philip S ^c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

direct thrombin inhibitors; meta analysis; orthopedic surgery; prophylaxis; venous thromboembolism; ximelagatran

Indexed keywords

ANTICOAGULANT AGENT; AZETIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE; HEPARIN; THROMBIN; WARFARIN; XIMELAGATRAN;

DRUG ADMINISTRATION; DRUG ANTAGONISM; HUMAN; META ANALYSIS; ORAL DRUG ADMINISTRATION; ORTHOPEDIC SURGERY; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; DRUG ADMINISTRATION SCHEDULE; HEPARIN; HUMANS; ORTHOPEDIC PROCEDURES; RISK ASSESSMENT; THROMBIN; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 67649992641     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029608326166     Document Type: Article

References (36)

1. Freedman KB, Brookenthal KR, Fitzgerald RH Jr, Williams S., Lonner JH A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am. 2000;82: 929-938.
2. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126: 338S-400S.
3. Levine MN, Gent M., Hirsh J., et al. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. Arch Intern Med. 1996; 156: 851-856.
4. Stulberg BN, Insall JN, Williams GW, Ghelman B. Deep-vein thrombosis following total knee replacement. An analysis of six hundred and thirty-eight arthroplasties. J Bone Joint Surg Am. 1984; 66: 194-201.
5. Todd CJ, Freeman CJ, Camilleri-Ferrante C., et al. Differences in mortality after fracture of hip: the east Anglian audit. BMJ. 1995; 310: 904-908.
6. Warwick DJ, Whitehouse S. Symptomatic venous thromboembolism after total knee replacement. J Bone Joint Surg Br. 1997; 79: 780-786.
7. White RH, Romano PS, Zhou H., Rodrigo J., Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998; 158: 1525-1531.
8. Gustafsson D., Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res. 2003;109: S9-S15.
9. Cohen AT, Hirst C., Sherrill B., Holmes P., Fidan D. Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery. Br J Surg. 2005; 92: 1335-1344.
10. Colwell C., Mouret P. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery. Semin Vasc Med. 2005; 5: 266-275.
11. Dager WE, Vondracek TG, McIntosh BA, Nutescu EA Ximelagatran: an oral direct thrombin inhibitor. Ann Pharmacother. 2004; 38: 1881-1897.
12. Eriksson BI Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. Thromb Res. 2003; 109: S23-S29.
13. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy. Prescrire Int. 2005;14: 127-132.
14. Lau J., Ioannidis JPA, Schmid CH Quantitative synthesis in systematic reviews. Ann Intern Med. 1997; 127: 820-826.
15. Thompson SG Why sources of heterogeneity in meta-analysis should be investigated. BMJ. 1994; 309: 1351-1355.
16. Song F., Sheldon TA, Sutton AJ, Abrams KR, Jones DR Methods for exploring heterogeneity in meta-analysis. Eval Health Prof. 2001; 24: 126-151.
17. Jadad AR, Moore RA, Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1-12.
18. Schulz KF, Grimes DA Allocation concealment in randomised trials: defending against deciphering. Lancet. 2002; 359: 614-618.
19. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188.
20. Cochran WG The Combination of Estimates from Different Experiments. Biometrics. 1954; 10: 101-129.
21. Higgins JP, Thompson SG Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21: 1539-1558.
22. Colwell CW Jr, Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost. 2003; 1: 2119-2130.
23. Colwell CW Jr, Berkowitz SD, Lieberman JR, et al. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am. 2005; 87: 2169-2177.
24. Eriksson BI, Arfwidsson AC, Frison L., Eriksson UG, Bylock A., Kalebo P., et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost. 2002;87: 231-237.
25. Eriksson BI, Agnelli G., Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. The METHRO III Study. Thromb Haemost. 2003;89: 288-296.
26. Eriksson BI, Agnelli G., Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost. 2003; 1: 2490-2496.
27. Eriksson BI, Bergqvist D., Kalebo P., et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet. 2002; 360: 1441-1447.
28. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003; 349: 1703-1712.
29. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med. 2002; 137: 648-655.
30. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med. 2001; 161: 2215-2221.
31. Colwell CW, Berkowitz SD, Comp PC, et al. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B. Blood. 2003; 102: Abstract 39.
32. Food and Drug Administration. Statistical Review and Evaluation. Clinical Studies. Exanta. NDA/Serial number 21-686. Accessed April 19, 2005.
33. Food and Drug Administration. EXANTA (Ximelagatran) Tablets NDA 21-686 FDA Advisory Committee Briefing Document. Cardiovascular and renal drugs advisory comittee. Accessed April 19, 2005.
34. He R. Food and Drug Administration. Integrated Executive Summary of FDA Review for NDA 21-686 Exanta (Ximelagatran). Accessed April 19, 2005.
35. Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty. A systematic review. Arch Intern Med. 2001; 161: 1952-1960.
36. Strebel N., Prins M., Agnelli G., Buller HR Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med. 2002; 162: 1451-1456.